184 related articles for article (PubMed ID: 3471687)
1. Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system.
Sakamoto K; Haga Y; Yoshimura R; Egami H; Yokoyama Y; Akagi M
Gut; 1987 Mar; 28(3):323-9. PubMed ID: 3471687
[TBL] [Abstract][Full Text] [Related]
2. [Diagnostic value of a new serum marker of human digestive cancer: the carbohydrate antigen 19.9; comparison with the carcinoembryonic antigen].
Olsson NO; Crimet-Montange D; Martin F
Gastroenterol Clin Biol; 1985 Mar; 9(3):206-11. PubMed ID: 3859449
[TBL] [Abstract][Full Text] [Related]
3. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.
Kuusela P; Haglund C; Roberts PJ
Br J Cancer; 1991 Apr; 63(4):636-40. PubMed ID: 2021550
[TBL] [Abstract][Full Text] [Related]
4. [CA 19-9 in neoplasms. Comparison with CEA].
Nakad A; Jonard P; Geubel A; Warzee P; Coppens JP; Dehennin JP; Dive C
Acta Gastroenterol Belg; 1987; 50(1):36-44. PubMed ID: 3480669
[No Abstract] [Full Text] [Related]
5. [Clinical evaluation of the tumor marker CA 19-9 in comparison with carcinoembryonic antigen (CEA) in surgical pre- and postoperative diagnosis].
Lorenz M; Happ J; Hottenrott C; Maul FD; Baum RP; Hör G; Encke A
Nuklearmedizin; 1986 Feb; 25(1):9-14. PubMed ID: 3459133
[TBL] [Abstract][Full Text] [Related]
6. [Usefulness of the determination of CA 19-9 in the follow-up of patients with gastroenteric neoplasms in comparison to CEA].
Pecchio F; Piantino P; Oliaro A; Rapellino M; Ricci E; Aimo G; Obert R
Minerva Med; 1986 Nov; 77(42-43):1973-81. PubMed ID: 3464850
[TBL] [Abstract][Full Text] [Related]
7. A clinical evaluation of carbohydrate antigen 19-9 and carcinoembryonic antigen in patients with pancreatic carcinoma.
Satake K; Kanazawa G; Kho I; Chung YS; Umeyama K
J Surg Oncol; 1985 May; 29(1):15-21. PubMed ID: 3857396
[TBL] [Abstract][Full Text] [Related]
8. [CA 12-5 in cancer of the digestive tract. A comparison with CA 19-9 and CEA in cancer of the pancreas and colon].
Klapdor R; Klapdor U; Bahlo M; Dallek M; Kremer B; van Ackeren H; Schreiber HW; Greten H
Dtsch Med Wochenschr; 1984 Dec; 109(51-52):1949-54. PubMed ID: 6595110
[TBL] [Abstract][Full Text] [Related]
9. Tumour marker CA 125 in patients with digestive tract malignancies.
Haglund C; Kuusela P; Roberts P; Jalanko H
Scand J Clin Lab Invest; 1991 May; 51(3):265-270. PubMed ID: 1715601
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.
Satake K; Kanazawa G; Kho I; Chung Y; Umeyama K
Am J Gastroenterol; 1985 Aug; 80(8):630-6. PubMed ID: 2411125
[TBL] [Abstract][Full Text] [Related]
11. [Serum level of tumor markers (antigen Ca 19-9, CEA, ferritin) in digestive tumors. Their diagnostic usefulness].
Jovin G; Stănel I; Popovici I; Oproiu A
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1988; 40(3):223-9. PubMed ID: 2904162
[No Abstract] [Full Text] [Related]
12. Serum sialyl-Tn antigen levels in patients with digestive cancers.
Motoo Y; Kawakami H; Watanabe H; Satomura Y; Ohta H; Okai T; Makino H; Toya D; Sawabu N
Oncology; 1991; 48(4):321-6. PubMed ID: 1891175
[TBL] [Abstract][Full Text] [Related]
13. Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.
Kuusela P; Haglund C; Roberts PJ; Jalanko H
Br J Cancer; 1987 Jun; 55(6):673-6. PubMed ID: 2441731
[TBL] [Abstract][Full Text] [Related]
14. [Study on the clinical usefulness of NCC-ST-439 in cases of digestive tract cancer].
Anzai K; Kurihara M; Izumi T
Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1437-47. PubMed ID: 2212836
[TBL] [Abstract][Full Text] [Related]
15. Tumour markers in pancreatic cancer.
Haglund C; Roberts PJ; Kuusela P; Jalanko H
Scand J Gastroenterol Suppl; 1986; 126():75-8. PubMed ID: 3470921
[TBL] [Abstract][Full Text] [Related]
16. Tumour markers CA 19-9 and CA 50 in digestive tract malignancies.
Haglund C; Roberts PJ; Jalanko H; Kuusela P
Scand J Gastroenterol; 1992; 27(3):169-74. PubMed ID: 1502477
[TBL] [Abstract][Full Text] [Related]
17. Carcinoembryonic antigen (CEA) and gastrointestinal cancer associated antigen CA 19-9 in bronchioloalveolar carcinomas and pulmonary adenocarcinomas.
Heikkilä L; Suomalainen RJ; Lindgren J; Jalanko H; Harjula A; Mattila S
Ann Chir Gynaecol; 1986; 75(5):260-5. PubMed ID: 3030184
[TBL] [Abstract][Full Text] [Related]
18. The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignancies.
Staab HJ; Brümmendorf T; Hornung A; Anderer FA; Kieninger G
Klin Wochenschr; 1985 Feb; 63(3):106-15. PubMed ID: 3856076
[TBL] [Abstract][Full Text] [Related]
19. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
[TBL] [Abstract][Full Text] [Related]
20. Tissue distribution of 2-3 and 2-6 sialyl Lewis A antigens and significance of the ratio of two antigens for the differential diagnosis of malignant and benign disorders of the digestive tract.
Itai S; Nishikata J; Yoneda T; Ohmori K; Yamabe H; Arii S; Tobe T; Kannagi R
Cancer; 1991 Mar; 67(6):1576-87. PubMed ID: 2001547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
